Grasso LFS - Search Results

1

Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas.

Tortora F, Negro A, Grasso LFS, Colao A, Pivonello R, Splendiani A, Brunese L, Caranci F. Tortora F, et al. Among authors: grasso lfs. Gland Surg. 2019 Sep;8(Suppl 3):S150-S158. doi: 10.21037/gs.2019.06.04. Gland Surg. 2019. PMID: 31559182 Free PMC article.

2

Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months.

Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Grasso LF, Lombardi G. Colao A, et al. J Clin Endocrinol Metab. 2008 Sep;93(9):3436-42. doi: 10.1210/jc.2008-0424. Epub 2008 Jul 1. J Clin Endocrinol Metab. 2008. PMID: 18593770

3

Medical therapy of pituitary adenomas: effects on tumor shrinkage.

Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G. Colao A, et al. Rev Endocr Metab Disord. 2009 Jun;10(2):111-23. doi: 10.1007/s11154-008-9107-z. Rev Endocr Metab Disord. 2009. PMID: 18791829 Review.

4

Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal.

Auriemma RS, Galdiero M, Grasso LF, Vitale P, Cozzolino A, Lombardi G, Colao A, Pivonello R. Auriemma RS, et al. Eur J Endocrinol. 2010 May;162(5):993-9. doi: 10.1530/EJE-09-0769. Epub 2010 Feb 15. Eur J Endocrinol. 2010. PMID: 20156970

5

Therapy of aggressive pituitary tumors.

Colao A, Grasso LF, Pivonello R, Lombardi G. Colao A, et al. Expert Opin Pharmacother. 2011 Jul;12(10):1561-70. doi: 10.1517/14656566.2011.568478. Epub 2011 Mar 24. Expert Opin Pharmacother. 2011. PMID: 21434849 Review.

6

Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?

Grasso LF, Pivonello R, Colao A. Grasso LF, et al. Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):288-94. doi: 10.1097/MED.0b013e328354af67. Curr Opin Endocrinol Diabetes Obes. 2012. PMID: 22627686 Review.

7

Investigational therapies for acromegaly.

Grasso LF, Pivonello R, Colao A. Grasso LF, et al. Expert Opin Investig Drugs. 2013 Aug;22(8):955-63. doi: 10.1517/13543784.2013.805201. Epub 2013 Jun 3. Expert Opin Investig Drugs. 2013. PMID: 23731031 Review.

8

Adverse events associated with somatostatin analogs in acromegaly.

Grasso LF, Auriemma RS, Pivonello R, Colao A. Grasso LF, et al. Expert Opin Drug Saf. 2015 Aug;14(8):1213-26. doi: 10.1517/14740338.2015.1059817. Expert Opin Drug Saf. 2015. PMID: 26184380 Review.

9

The safety of treatments for prolactinomas.

Auriemma RS, Grasso LF, Pivonello R, Colao A. Auriemma RS, et al. Expert Opin Drug Saf. 2016;15(4):503-12. doi: 10.1517/14740338.2016.1151493. Epub 2016 Mar 7. Expert Opin Drug Saf. 2016. PMID: 26855238 Review.

10

Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly.

Grasso LFS, Auriemma RS, Pivonello R, Colao A. Grasso LFS, et al. Expert Rev Endocrinol Metab. 2017 Jan;12(1):73-85. doi: 10.1080/17446651.2016.1222899. Epub 2016 Sep 7. Expert Rev Endocrinol Metab. 2017. PMID: 30058878

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

148 results

Search Page